Original
Eficacia y seguridad de empagliflozina en combinación con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus
Irene Romeraa,
, Francisco Javier Ampudia-Blascob, Antonio Pérezc, Bernat Ariñod, Egon Pfarre, Sanja Giljanovic Kisf, Ebrahim Naderalig,h
Autor para correspondencia
a Eli Lilly and Company España, Alcobendas, Madrid, España
b Hospital Clínico Universitario de Valencia, Valencia, España
c Hospital de la Santa Creu i Sant Pau, Barcelona, España
d Boehringer Ingelheim Pharma GmbH & Co., España, Sant Cugat del Vallès, Barcelona, España
e Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Alemania
f Eli Lilly (Suisse) SA Representative Office, Croatia, Zagreb, Croacia
g Eli Lilly and Company, UK, Basingstoke, Reino Unido
h Faculty of Science, Liverpool Hope University, Liverpool, Reino Unido
Leído
109420
Vecesse ha leído el artículo
5391
Total PDF
104029
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 119 | 7 | 126 |
| 2025 11 | 782 | 37 | 819 |
| 2025 10 | 1067 | 60 | 1127 |
| 2025 9 | 1501 | 50 | 1551 |
| 2025 8 | 671 | 41 | 712 |
| 2025 7 | 650 | 42 | 692 |
| 2025 6 | 708 | 24 | 732 |
| 2025 5 | 3412 | 10 | 3422 |
| 2025 4 | 7714 | 46 | 7760 |
| 2025 3 | 9968 | 40 | 10008 |
| 2025 2 | 4420 | 32 | 4452 |
| 2025 1 | 969 | 29 | 998 |
| 2024 12 | 3489 | 31 | 3520 |
| 2024 11 | 3367 | 46 | 3413 |
| 2024 10 | 1100 | 49 | 1149 |
| 2024 9 | 1725 | 58 | 1783 |
| 2024 8 | 964 | 51 | 1015 |
| 2024 7 | 1001 | 44 | 1045 |
| 2024 6 | 840 | 40 | 880 |
| 2024 5 | 794 | 35 | 829 |
| 2024 4 | 1189 | 34 | 1223 |
| 2024 3 | 1012 | 47 | 1059 |
| 2024 2 | 746 | 58 | 804 |
| 2024 1 | 1361 | 56 | 1417 |
| 2023 12 | 1165 | 60 | 1225 |
| 2023 11 | 4214 | 61 | 4275 |
| 2023 10 | 3294 | 103 | 3397 |
| 2023 9 | 2822 | 66 | 2888 |
| 2023 8 | 3143 | 55 | 3198 |
| 2023 7 | 1022 | 82 | 1104 |
| 2023 6 | 1244 | 69 | 1313 |
| 2023 5 | 2444 | 84 | 2528 |
| 2023 4 | 1252 | 72 | 1324 |
| 2023 3 | 3299 | 65 | 3364 |
| 2023 2 | 2101 | 63 | 2164 |
| 2022 1 | 1743 | 67 | 1810 |
| 2022 12 | 682 | 56 | 738 |
| 2022 11 | 1520 | 74 | 1594 |
| 2022 10 | 1122 | 55 | 1177 |
| 2022 9 | 1105 | 93 | 1198 |
| 2022 8 | 1127 | 87 | 1214 |
| 2022 7 | 865 | 63 | 928 |
| 2022 6 | 544 | 125 | 669 |
| 2022 5 | 509 | 60 | 569 |
| 2022 4 | 502 | 53 | 555 |
| 2022 3 | 476 | 73 | 549 |
| 2022 2 | 475 | 80 | 555 |
| 2021 1 | 462 | 79 | 541 |
| 2021 12 | 479 | 61 | 540 |
| 2021 11 | 569 | 82 | 651 |
| 2021 10 | 579 | 65 | 644 |
| 2021 9 | 553 | 68 | 621 |
| 2021 8 | 585 | 49 | 634 |
| 2021 7 | 429 | 35 | 464 |
| 2021 6 | 346 | 46 | 392 |
| 2021 5 | 403 | 76 | 479 |
| 2021 4 | 1024 | 74 | 1098 |
| 2021 3 | 586 | 72 | 658 |
| 2021 2 | 455 | 50 | 505 |
| 2020 1 | 406 | 68 | 474 |
| 2020 12 | 307 | 74 | 381 |
| 2020 11 | 338 | 37 | 375 |
| 2020 10 | 221 | 73 | 294 |
| 2020 9 | 218 | 61 | 279 |
| 2020 8 | 272 | 64 | 336 |
| 2020 7 | 281 | 42 | 323 |
| 2020 6 | 280 | 47 | 327 |
| 2020 5 | 322 | 56 | 378 |
| 2020 4 | 286 | 28 | 314 |
| 2020 3 | 280 | 46 | 326 |
| 2020 2 | 299 | 43 | 342 |
| 2020 1 | 249 | 13 | 262 |
| 2019 12 | 2008 | 52 | 2060 |
| 2019 11 | 524 | 41 | 565 |
| 2019 10 | 343 | 54 | 397 |
| 2019 9 | 415 | 57 | 472 |
| 2019 8 | 289 | 41 | 330 |
| 2019 7 | 312 | 48 | 360 |
| 2019 6 | 270 | 71 | 341 |
| 2019 5 | 300 | 163 | 463 |
| 2019 4 | 423 | 129 | 552 |
| 2019 3 | 196 | 74 | 270 |
| 2019 2 | 213 | 58 | 271 |
| 2019 1 | 152 | 54 | 206 |
| 2018 12 | 130 | 22 | 152 |
| 2018 11 | 153 | 66 | 219 |
| 2018 10 | 283 | 25 | 308 |
| 2018 9 | 126 | 27 | 153 |
| 2018 8 | 105 | 30 | 135 |
| 2018 7 | 69 | 29 | 98 |
| 2018 6 | 87 | 36 | 123 |
| 2018 5 | 101 | 31 | 132 |
| 2018 4 | 100 | 16 | 116 |
| 2018 3 | 109 | 16 | 125 |
| 2018 2 | 74 | 14 | 88 |
| 2018 1 | 105 | 19 | 124 |
| 2017 12 | 82 | 11 | 93 |
| 2017 11 | 99 | 24 | 123 |
| 2017 10 | 107 | 23 | 130 |
| 2017 9 | 93 | 27 | 120 |
| 2017 8 | 69 | 20 | 89 |
| 2017 7 | 68 | 25 | 93 |
| 2017 6 | 86 | 25 | 111 |
| 2017 5 | 8 | 0 | 8 |
| 2017 4 | 3 | 0 | 3 |
| 2017 3 | 7 | 1 | 8 |
| 2017 2 | 15 | 0 | 15 |
| 2016 1 | 15 | 1 | 16 |
| 2016 12 | 15 | 0 | 15 |
| 2016 11 | 7 | 2 | 9 |
| 2016 10 | 0 | 12 | 12 |
| 2016 9 | 0 | 5 | 5 |
Mostrar todo
